Related Experiment Videos
Teicoplanin--home therapy for prosthetic joint infections
P G Davey1, D R Rowley, G A Phillips
1Department of Clinical Pharmacology, Ninewells Hospital, Dundee, UK.
Abstract:
Infection with methicillin-resistant organisms is increasingly common among implanted orthopaedic devices. The organisms involved are often multiresistant to other commonly used antibiotics. Rifampicin resistance is less common at isolation but may develop during treatment unless combination therapy with another drug is employed. However, tolerance of combinations is poor, particularly among elderly patients. These patients may require at least 6 weeks of antibiotic therapy, and where there is no suitable oral therapy, this has meant prolonged hospitalization solely for administration of parenteral antibiotics. Recently we have started treating such patients with teicoplanin, 6 mg/kg once daily, by intravenous bolus injection. The injections are administered by relatives at home and the patients attend the ward twice weekly for inspection and changing of the intravenous cannula. The potential for home administration of parenteral teicoplanin gives this drug a major advantage over other parenteral drugs for the treatment of prosthetic joint infections.
Insights
Treating orthopedic infections from methicillin-resistant organisms with parenteral teicoplanin allows for home administration. This reduces prolonged hospitalization for elderly patients requiring long-term antibiotic therapy.
Area of Science:
- Orthopedic Surgery
- Infectious Diseases
- Pharmacology
Background:
- Increasing prevalence of methicillin-resistant organisms in orthopedic device infections.
- Multidrug resistance in causative organisms complicates treatment.
- Rifampicin resistance can emerge during monotherapy, necessitating combination treatment.
Purpose of the Study:
- To evaluate teicoplanin as a treatment for prosthetic joint infections.
- To assess the feasibility of home administration for parenteral antibiotics.
- To reduce hospitalization duration for patients with orthopedic device infections.
Main Methods:
- Treatment of patients with teicoplanin (6 mg/kg once daily) via intravenous bolus injection.
- Home administration of injections by patient relatives.
- Twice-weekly ward visits for cannula care and patient inspection.
Main Results:
- Teicoplanin enables parenteral antibiotic administration outside the hospital setting.
- Home administration by relatives simplifies treatment logistics.
- Potential to reduce hospital stay for patients requiring prolonged parenteral therapy.
Conclusions:
- Parenteral teicoplanin offers a significant advantage for treating prosthetic joint infections due to its home administration potential.
- This approach may improve tolerance and compliance in elderly patients.
- Reduces the burden of prolonged hospitalization for orthopedic device infections.